Supernus Pharmaceuticals, Inc. welcomed the decisive backing of shareholders today, who formally voted to approve the pending all-stock merger of equals.
This vote marks an important milestone toward completing the merger announced in August 2026, with closing anticipated on November 2, 2026, subject to customary closing conditions. Following closing, the combined organization will officially commence operations as Supernus, Inc., trading on the Nasdaq Global Market under the ticker symbol “SUPN.”
Once complete, the merger will unite two organizations with a shared dedication to neuroscience, establishing a scaled commercial platform spanning addiction, psychiatry, and neurology. Together, the combined company will possess the expanded capabilities, financial strength, and pipeline capacity to make a meaningful difference for people living with conditions such as opioid use disorder, ADHD, Parkinson’s disease, and depression, while delivering sustained, long-term value for shareholders.
Read more here.